GenSight Biologics SA 2023 IR
The report outlines GenSight Biologics S.A.'s operational and financial performance for the fiscal year 2023. Key highlights include the strategic decision to withdraw the EMA marketing authorization application for LUMEVOQ to address remaining objections, alongside plans for a new Phase III trial, RECOVER. The company implemented significant cash preservation measures, including a 40% headcount reduction, to extend its cash runway. Additionally, GenSight successfully manufactured two GMP batches of LUMEVOQ and secured a bridge financing agreement to support ongoing clinical and operational activities.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2023
Type: IR
Pages: 356
Back to company
GenSight Biologics SA
Universal Registration Document
The report outlines GenSight Biologics S.A.'s operational and financial performance for the fiscal year 2023. Key highlights include the strategic decision to withdraw the EMA marketing authorization application for LUMEVOQ to address remaining objections, alongside plans for a new Phase III trial, RECOVER. The company implemented significant cash preservation measures, including a 40% headcount reduction, to extend its cash runway. Additionally, GenSight successfully manufactured two GMP batches of LUMEVOQ and secured a bridge financing agreement to support ongoing clinical and operational activities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees